A review of cardiovascular outcome trials in type 2 diabetes.

@article{Cypryk2018ARO,
  title={A review of cardiovascular outcome trials in type 2 diabetes.},
  author={Katarzyna Cypryk and Piotr Paweł Małecki},
  journal={Endokrynologia Polska},
  year={2018},
  volume={69 4}
}
Type 2 diabetes is a complex metabolic disorder associated with a high risk of cardiovascular complications. In December 2008, due to concerns about the cardiac safety of antihyperglycaemic therapies, the Food and Drug Administration (FDA) published a new guidance on special requirements for the demonstration of cardiovascular safety for these medications. In 2012, similar recommendations were made for antidiabetic drug manufacturers by the European Medicines Agency (EMA). Since then, both FDA… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  • The New England journal of medicine
  • 2016
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL